Gracell Biotechnologies Inc.
gracellbio.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2022 20-F, filed Apr 25, 2023. Its latest SEC filing is a 15-12G from Mar 4, 2024.
20-F for FY2022, filed Apr 25, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Develops CAR-T cell therapies for cancer treatment, targeting blood cancers and solid tumors.
20-F for FY2022, filed Apr 25, 2023
Who Were Their Customers?
In China, the company works with hospitals running investigator-initiated trials and provides CAR-T cells to their principal investigators for administration to patients.
20-F for FY2022, filed Apr 25, 2023Leveraging our pioneering platforms, technology modules, know-how and experience, we are developing a rich clinical-stage pipeline of…View ↗
Who Did They Compete With?
Competes with Nanjing Legend Biotech, 2seventy bio, Allogene, Juno Therapeutics, Kite Pharma, Poseida Therapeutics, Autolus Therapeutics, and Novartis
20-F for FY2022, filed Apr 25, 2023Due to the promising clinical therapeutic effect of CAR-T product candidates in clinical trials, we anticipate direct competition from…View ↗
Loading...
